Selected Start-Ups (1/07)
In Vivo briefly summarizes the technologies of these recently founded companies: Acute Innovations, Advanced Liquid Logic, Cardioxyl Pharmaceuticals, OrthoMimetics, Predictive Biosciences, and TetraPhase Pharmaceuticals.
You may also be interested in...
Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?
Agenus was banking on US FDA taking the full six months to act on Keytruda application in same cervical cancer indication where it was seeking accelerated approval; agency took less than two months, making it among the fastest oncology supplemental approvals in the last two years.
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.